Thank you for your interest in participating in the Phase III Patidegib 2% topical gel clinical trial for the reduction of disease burden of basal cell carcinomas in Gorlin Syndrome sponsored by PellePharm. The participating sites in the US are listed below and is divided into three categories based upon their current status of enrollment.
Tier 1: Sites that are fully activated and can actively screen on-site and dose patients.
Tier 2: Sites that can pre-screen and where activation in eminent.
Tier 3: Sites that have committed to participating in the trial but have not completed activation yet.
Please note: If there is no site close to you or a site has not opened yet, but you are interested in participating now, PellePharm is reimbursing patients for travel to remote sites. However, you must be willing to commit to a monthly trip to that site for one year and you cannot switch to another site mid-study. As site status changes, this list will be updated accordingly, so please stay in touch with our office. If all goes as planned, all sites should move up to the tier 1 status within the next few months.
|Tier 1 – Sites that are fully activated and can actively screen on-site and dose patients.|
|State||Site Location||Site Investigator||Study Coordinator||Study Coordinator Contact Info|
|CT||New Haven (Yale)||Dr. Sean Christensen||Mahin Dawood||203.785.5505 or email@example.com|
|FL||Ormond Beach||Dr. James Solomon||Sandra Warrington||386.523.0768 or Sandra.firstname.lastname@example.org|
|IN||Indianapolis||Dr. William Hanke||Jami Zenor||317.660.4862 or email@example.com|
|MN||Minneapolis (Univ. of Minnesota)||Dr. Ian Maher||Irmina Wallander||612.624.5721 or firstname.lastname@example.org|
|CA||Redwood City (Stanford Univ.)||Dr. Anne Chang||Alexander Valencia||650.498.5185 or email@example.com|
|CA||San Francisco||Dr. Sarah Arron||Christine Aroyan||415.353.9684 or|
|MO||St. Louis (St. Louis Univ Hosp)||Dr. Patricia Missall||Rosemary King||314.256.3436 or firstname.lastname@example.org|
|OR||Portland||Dr. Anna Bar||Christina Armstrong||503.494.4770 or|
|NC||Durham||Dr. Meenal Kheterpal||Kim Scoggins||919-684-1830 or Kim.email@example.com|
|Tier 2 – Sites that can pre-screen and where activation in eminent.|
|Tier 3: Sites committed to participating in the trial but have not completed activation yet.|
|UT||Salt Lake City|
You can also learn more about this clinical trial by visiting www.gorlinstudy.com.